Bibliografía
1. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
2. Saro C, Lacort M, Argüelles G, Antón J, García R, Navascues CA, et al. Incidencia y prevalencia de la enfermedad inflamatoria intestinal en Gijón, Asturias, España. Gastroenterol Hepatol 2000;23:322-7.
3. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, et al. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2013;0:1–10. doi:10.1136/gutjnl-2013-304636.
4. Nerich V, Monnet E, Etienne A, Louafi S, Ramée C, Rican S, et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis 2006;12:218-26.
5. Sincic BM, Vucelic B, Persic M, Brncic N, Erzen DJ, Radakovic B, et al. Incidence of inflammatory bowel disease in Primorsko-Goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006;41:437-44.
6. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82.
7. Saro C, de la Coba C, Lacort M, González A, Álvarez A, Pérez-Pariente JM, et al. Changes in incidence of inflammatory bowel disease during the last 15 years: a epidemilogical prospective population-based study from Gijón (Spain) (1992-2006). Gut 2007;56 Suppl 3:A129.
8. Cohen RD. The quality of life in patients with Crohn´s disease. Aliment Pharmacol Ther 2002;16:1603-9.
9. Juan J, Estiarte R, Colomé E, Artés M, Jiménez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-61.
10. López-Vivancos J, Casellas F, Badía X, Vilaseca J, Malagelada JR. Validation of the Spanish version of the Inflammatory Bowel Disease Questionnaire in ulcerative colitis and Crohn´s disease. Digestion 1999;60:274-80.
11. Alcala MJ, Casellas F, Fontanet G, Prieto, L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:383-91.
12. Wyke RJ, Edwards FC, Allan RN. Employment problems and prospects for patients with inflammatory bowel disease. Gut 1988;29:1229-35.
13. Reilly MC, Gerlier L, Brown M. Discriminant validity of the work productivity and activity impairment questionnaire in patients with Crohn’s disease. Value Health 2006;9:A246-7.
14. Feagan B, Schreiber S, Selke B, Reilly MC, Sandborn WJ. Moderate to severe Crohn's disease induces high productivity losses: Work Productivity and Activity Impairment (WPAI) baseline data from the PRECiSE program. Gastroenterology 2006;130:A483.
15. Feagan B, Brown M, Gerlier L, Schreiber S. The effects of certolizumab pegol on work productivity and daily activities of Crohn's disease patients: Data from PRECISE 2. Gut 2007;55 Suppl V:A139.
16. Vergara M, Montserrat A, Casellas F, Maudsley M, Gallardo O, Ricart E, et al. Validation of the Spanish Work Productivity and Activity Impairment Questionnaire: Crohn’s disease version. Eur J Gastroenterol Hepatol 2009;21:809-15.
17. Vergara M, Montserrat A, Casellas F, Villoria A, Suarez D, Maudsley M, et al. A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version. Value Health 2011;14:859-61.
18. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
19. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85.
20. Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis 2013;7:34-43.
21. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The Effects of Infliximab Maintenance Therapy on Health-Related Quality of Life. AJG 2003;10(98):2232-38.
22. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
23. Koelewijn C, Schrijvers A, Oldenburg B. Infliximab use in patients with Crohn’s disease: quality of life, costs and resource use. The Netherland Journal of Medicine 2006;7(64):212-8.
24. Feagan BG, Panaccione R, Sandborn WJ, D’Haens GR, Scheireiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 2008;135:1493-9.
25. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn´s disease activity index. Gastroenterology 1976;70:439-44.
26. Irvine EJ. Usual therapy improves perianal Crohn´s Disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
27. Badía X, Fernández E, Segura A. Influence of socio-demographic and health status variables on evaluation of health status in a Spanish population. Eur J Public Health 1995;5:87-93.
28. van Balkom BP, Schoon EJ, Stockbrugger RW, Wolters FL, van Hogezand RA, van Deventer SJ, et al. Effects of anti-tumour necrosis factor-a therapy on the quality of life in Crohn’s disease. Aliment Pharmacol Ther 2002; 16: 1101–1107.
29. Binion DG, Louis E, Oldenburg B, Mulani P, Bensimon A, Yang M, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis. Can J gastroenterol 2011;25:492-6.
30. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228–39.
31. Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the Unites States for moderately to severely active Crohn’s disease. Pharmaeconomics 2009;27:609-21.
32. Casellas F, Robles V, Borruel N, Torrejón A, Castells I, Navarro E, et al. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment. Journal of Crohn's and Colitis (2012) 6, 881–886.